Elobixibat is an orally active, locally acting ileal bile acid transporter (IBAT) inhibitor. It works by inhibiting the reabsorption of bile acids in the terminal ileum, increasing the amount of bile acid delivered to the colon. This mechanism can stimulate colonic secretion and motility.
Elobixibat has been developed as a pharmaceutical treatment for chronic constipation, particularly in Japan, where it is marketed for chronic constipation under the brand name Goofice.
Elobixibat has the CAS Registry Number 439087-18-2 and is a small-molecule pharmaceutical compound.
Elobixibat API is an active pharmaceutical ingredient used in the development and manufacture of medicines targeting chronic constipation through inhibition of the intestinal bile acid transport pathway.
Its mechanism is different from conventional stimulant or osmotic laxatives because it increases endogenous bile acid delivery to the colon by inhibiting intestinal bile acid reabsorption.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | NMT 1.0% |
| Melting Point | 150°C – 154°C |